ARW ON RNA
5 Critical Regulatory Topics To Watch In The Oligo Sector
Though our guidances have helped us achieve upwards of 20 commercially approved oligo products, as I listened to GSK’s director of CMC policy and advocacy, Katie Duncan, present at TIDES, it struck me just how far we have yet to come. Here, I single out a few of the biggest topics of regulatory discussion shaping the oligo therapeutics market.
OUR EXPERT NETWORK
-
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics
CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery
As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check
A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.
-
Building A Self-Driving Lab For LNP Development
With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
-
Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate
How do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.
WEBINARS
MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
RNA HOT TAKES
- Sticks, Carrots, & Carolina Reapers: Fact-Checking The "Death" Of The US mRNA Industry
- mRNA Hot Takes: Ghost Peppers & Global R&D
- mRNA Hot Takes: Habaneros & Headwinds
- The Trough Of Disillusionment: 2026 RNA Reality Checks
- mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026
- mRNA Hot Takes: Building A Solid Foundation For Your RNA Company & Products
VIRTUAL EVENTS
- Evolutions in mRNA Drug Product Analytical Development
- Closing The Adoption Gap For Advanced Single-Use Materials
- Advancements in gRNA Manufacturing & Quality
- Chemoenzymatic Ligation: A New Frontier In siRNA Manufacturing
- Advancements In Targeted LNP Therapy
- Unlocking The Future: Innovations In The mRNA And Oligo Supply Chains
NEWSLETTER ARCHIVE
- 07.22.26 -- RNA Platforms: What Transfers And What Breaks
- 07.15.26 -- Where Enzymatic Ligation Of siRNA Stands Today
- 07.14.26 -- Practical Strategies for Contamination Control and EM Compliance
- 07.08.26 -- Why The Next Era Of siRNA Belongs In Cardiology
- 07.03.26 -- Advancing RNA Newsletter Best Of June
- 07.01.26 -- A Mid-Year Look At The 2026 Life Sciences Industry